Press release content from Business Wire. The AP news staff was not involved in its creation.
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
July 13, 2021 GMT
NEW YORK (BUSINESS WIRE) Jul 12, 2021
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,747,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company.
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
News provided by
Share this article
Share this article
GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering, today announced the public filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the
SEC ) relating to a proposed dual listing of its shares of common stock on the Nasdaq Global Market (
Nasdaq ) under the symbol MXCT. As part of the proposed Nasdaq dual listing, MaxCyte is planning a public offering of shares of its common stock in the United States (the
MIL-OSI: Paycor Announces Launch of Initial Public Offering foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
July 01, 2021 21:50 ET | Source: Cerevel Therapeutics Cerevel Therapeutics Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.